Back to homepage Our offer: Strain collections

Large strain collections available for your projects!

Are you looking for specific strains? Smaltis and its network of partners will do everything to find them for you!

Indeed, Smaltis offers you the provision of bacterial or fungal strains from various collections, with the aim of allowing you to use microbial resources specifically tailored to your needs. These strains can be used directly in the manipulations we implement for your projects, or, in some cases, they can be transmitted to you so that you can carry out your experiments successfully.

Patient-Derived Strains

Through its exclusive collaboration with the Biologic Resource Center – Filière Microbiologique de Besançon (CRB-FMB) at the Jean Minjoz University Hospital, Smaltis provides access to over 80,000 strains isolated from hospitalized patients suffering from various pathologies. These clinical isolates are cataloged based on geography, year of isolation, antibiotic resistance phenotype, sample source, and patient demographic data. Each strain is accompanied by the date and sampling conditions, patient’s clinical status and whether antibiotic therapy was prescribed or not.

Reference Strains

Furthermore, Smaltis offers the opportunity to conduct work on reference strains sourced from various bioresources such as ATCC, DSMZ, BCCM COLLECTIONS, Westerdijk Fungal Biodiversity Institute, Institut Pasteur (CIP), and more. Among the species we already possess are Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and various Enterobacter species.

Genetically Modified Bacterial Strains

Through its expertise in molecular biology, Smaltis has established collections of genetically modified bacterial strains that can be used in your projects. These strains are characterized both phenotypically and genotypically.

Strains for Early Antibiotic resistance Study

Since its establishment, Smaltis has been building proprietary mutant banks specific to different species such as Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. These mutants exhibit different antibiotic resistance profiles and are characterized within well-controlled genetic backgrounds. Among the targeted resistance mechanisms are active efflux, enzyme production, and antibiotic target mutations. These mutant banks, designed specifically for the early study of the role and nature of resistance mechanisms commonly found in clinical settings, allow for anticipating the adaptation of microorganisms to future antimicrobial molecules.

Strains for Bioproduction

In addition to the study of antibiotic resistance, Smaltis also invests in the development of tools for bioproduction. Consequently, Smaltis owns a strain of Escherichia coli BL21 with deleted genes encoding for phage DE3, constructed on animal-free media.
Smaltis also possesses a chassis derived from the reference strain of Pseudomonas aeruginosa PAO1, which is hypersensitive to antibiotics and hypovirulent. Additionally, finely controlled and inducible expression plasmids are available. These tools are accessible through licensing for commercial activities.
If your desired strain is not available in the catalog, we can tailor-build it for you! (see our Bioproduction offer)

Support Service: Strain and Product Storage

Additionally, Smaltis offers dedicated storage space specifically designed for microorganisms and pharmaceutical products, available for an unlimited duration. This storage is maintained at a controlled temperature of -80°C, with a continuous alarm system.

This storage solution enables you to have a secure backup of your bacterial or fungal strains or to store pharmaceutical products until they are needed. A storage certificate is regularly provided, including details related to the preservation, and is updated with each modification.

This service ensures the longevity and safety of your valuable microbial resources and pharmaceutical products, allowing you to access them whenever necessary, supported by a comprehensive documentation and monitoring system.

Our partners and networks

News and articles

ECCMID – ESCMID Global

Smaltis attends the 34th edition of the ECCMID international congress, renamed ESCMID Global, in Barcelona from April 27 to 30, 2024. This clinical microbiology and infectious diseases event is one of the largest and most important congresses in the field of infection, bringing together over 16,000 participants from all over the world to contribute to the dissemination of scientific knowledge.

READ THE POST

Sanofi Vaccines R&D Day

Smaltis attends the Sanofi Vaccines R&D Day, organized by Sanofi in partnership with Lyonbiopôle, Enosis Santé and Polepharma!
This event aims to foster partnerships around 5 themes: antimicrobial approaches, therapeutic vaccines and antibodies, mucosal or skin delivery of vaccines, immunology, and antigen design. Quite a program!

Cédric Muller will be present at this event, which will take place on April 11, 2024, at 14 Espace Henry Vallée in Lyon.

READ THE POST

Viruses at the service of humanity?

Once upon a time, the English bacteriologist Ernest Hankin demonstrated for the first time the presence of anti-bacterial entities in the waters of Indian rivers, putting humanity on the path to a promising anti-infectious therapy that is more relevant than ever.

READ THE POST

Microbiota & Health Day 7th edition

Smaltis is delighted to be taking part in the 7th edition of Microbiota & Health Day, organized by Lyonbiopôle and Alliance Promotion Microbiote, on March 26, 2024 in Lyon. The aim of this day is to bring together academic, clinical and industrial players to discuss topical issues that are driving innovation in the field of microbiota and their impact on health.

READ THE POST

AMR Conference 8th edition

Smaltis is happy to participate to the 8th edition of AMR Conference in Basel from March 6th to 7th 2024, a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and specific challenges faced by the innovation ecosystem in bringing new antimicrobial treatments and diagnostics to the market.

READ THE POST

The same… But better!

The year 2024 marks the 10th anniversary (already!) of the Smaltis adventure! 10 years of microbiology, 10 years of molecular biology, 10 years of passion, 10 years of twists and turns, 10 years of growth, 10 years of self-reflection, 10 years of continuous improvement, 10 years of scientific spirit, 10 years of ambition, 10 years of collaboration, 10 years of human relationships…

It was necessary to celebrate this milestone, and not just by blowing out the candles.

READ THE POST

The Polepharma Microbiomics Days

Smaltis is delighted to have participated in and sponsored, for the fourth consecutive year, the Polepharma Microbiomics Days, held in Rouen on November 22 and 23, 2023.

READ THE POST

The man who wanted to extend lifespan

Once upon a time, more than a century ago, Elie Metchnikoff hypothesized that health could be improved, and senility delayed by modulating the intestinal microbes thanks to bacteria present in yogurt. This zoologist and microbiologist was thus one of the first scientists to take an interest in gut microbiota and what we now call probiotics, the consumption of which he claimed helped to fight against aging.

This is the story of “the man who wanted to extend lifespan”.

READ THE POST

All our sincere wishes

In this new year that begins, let’s take the time…

Let’s take the time to extend our best wishes to you, from the bottom of our hearts. It seems essential to us, during these periods conducive to gratitude, to prioritize human relationships as the most important aspect of our lives.

READ THE POST